Page 2 - ஒன்றுபட்டது சிகிச்சை நிறுவனம் நாஸ்டாக் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

United Therapeutics Corporation Reports First Quarter 2021 Financial Results Tyvaso® (treprostinil) Inhalation Solution approved for pulmonary hypertension associated with interstitial lung disease (PH-ILD) Tyvaso DPI™ New Drug Application (NDA) submitted to U.S. Food and Drug Administration TETON study of Tyvaso in idiopathic pulmonary fibrosis (IPF) expected to enroll its first patients in the second quarter of 2021 News provided by Share this article Share this article SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 5, 2021 /PRNewswire/  United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended March 31, 2021. Total revenue in the first quarter of 2021 grew 6% year over year to $379.1 million, compared to $356.3 million in the first quarter of 2020.

United statesMichael benkowitzEli lillyDewey steadmanMartine rothblattExchange commissionUnited therapeutics corporation nasdaqResearch development corpUnited therapeutics corporationUnited therapeuticsChief executive officerChief operating officerRemunity pumpRemodulin in februaryInhalation solutionNew england journal